Breaking News Instant updates and real-time market news.

ALLO

Allogene Therapeutics

$28.01

-0.14 (-0.50%)

, CELG

Celgene

$90.21

-0.69 (-0.76%)

08:19
07/22/19
07/22
08:19
07/22/19
08:19

American Association for Cancer Research to hold a conference

Immune Cell Therapies for Cancer will be held in San Francisco on July 19-22.

ALLO

Allogene Therapeutics

$28.01

-0.14 (-0.50%)

CELG

Celgene

$90.21

-0.69 (-0.76%)

UMRX

Unum Therapeutics

$2.62

-0.01 (-0.38%)

CLDX

Celldex

$2.37

0.01 (0.42%)

ZIOP

Ziopharm

$5.49

-0.16 (-2.83%)

  • 22

    Jul

  • 03

    Sep

  • 09

    Sep

  • 12

    Sep

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

ALLO Allogene Therapeutics
$28.01

-0.14 (-0.50%)

05/30/19
05/30/19
INITIATION
Target $25

Buy
Rubius Therapeutics, Fate Therapeutics initiated with a Buy at Guggenheim
As previously reported, Guggenheim analyst Michael Schmidt initiated Rubius Therapeutics (RUBI) and Fate Therapeutics (FATE) with a Buy rating and Allogene Therapeutics (ALLO) with a Neutral rating as part of a broader research note of 3 biotechnology stocks that developed "innovative" next-gen cell therapy platforms. The analyst has a $25 price target on Fate Therapeutics, saying the company could "leapfrog" competitors by applying its induced pluripotent stem cell, or iPSC, platform toward "engineered off-the-shelf cancer immunotherapies in a dish". While still at an early stage, Schmidt says the platform may improve upon its initial shortcomings in first and also second generation cellular cancer immunotherapies toward a broad set of therapeutic areas. The analyst is also positive on the "unique red cell therapeutics platform" of Rubius Therapeutics and its upcoming proof-of-concept data in the second half of this year, with an "extremely broad" range of potential applications including rare genetic diseases to cancer and autoimmune diseases. Schmidt also assigns $25 price target to Rubius. For Allogene Therapeutics, Schmidt says he is positive on its potential front-runner status in bringing off-the-shelf CAR-T to market, but sees much of its potential having been priced into the stock.
05/30/19
GUGG
05/30/19
INITIATION
GUGG
Neutral
Allogene Therapeutics initiated with a Neutral at Guggenheim
Guggenheim analyst Michael Schmidt started Allogene Therapeutics with a Neutral rating.
05/23/19
05/23/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Elanco (ELAN) initiated with a Neutral at Guggenheim. 2. Cooper Tire (CTB) initiated with an Overweight at KeyBanc while Goodyear Tire (GT) was initiated with a Sector Weight. 3. SciPlay (SCPL) initiated with a Buy at Craig-Hallum and an Overweight at Stephens. 4. Target Hospitality (TH) initiated with an Outperform at Credit Suisse and Oppenheimer. 5. Allogene Therapeutics (ALLO) initiated with a Hold at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/05/19
ROTH
06/05/19
INITIATION
Target $26
ROTH
Neutral
Allogene Therapeutics initiated with a Neutral at Roth Capital
Roth Capital analyst Tony Butler started Allogene Therapeutics with a Neutral rating and $26 price target. Allogene has a "strong team, a strong platform, and access to significant resources to continue development efforts," Butler tells investors in a research note. However, he believes the market has "somewhat priced" these into the stock at current levels.
CELG Celgene
$90.21

-0.69 (-0.76%)

06/25/19
WBLR
06/25/19
NO CHANGE
WBLR
Outperform
Bristol-Myers sentiment suffered 'double hit' yesterday, says William Blair
William Blair analyst Matt Phipps said Bristol-Myers (BMY) suffered a "double hit to sentiment" yesterday with the news of both the CheckMate-459 trial failure in first-line hepatocellular carcinoma and delay of the closing of its Celgene (CELG) deal due to the required Otezla divestiture. He had previously modeled Opdivo sales in the front-line setting of over $1B and Otezla sales growing to $3B before loss of exclusivity in 2028 and decreased his out-year EPS estimates by over $1.00 due to yesterday's news. However, although near-term sentiment is dampened, he still sees a long-term opportunity, said Phipps, who keeps an Outperform rating on Bristol-Myers shares.
06/24/19
CANT
06/24/19
NO CHANGE
Target $100
CANT
Neutral
Celgene pushback surprising, but deal should still close, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young said she was surprised by the FTC pushback around Otezla and its overlap in psoriasis related to Celgene's (CELG) oral TYK2 program BMS-986165 in psoriasis given that the latter has not yet reported Phase 3 data. After speaking to Bristol-Myers (BMY), Young said management was also disappointed in this FTC decision, which they said was not related to current asset Orencia marketed for rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. Though timelines are delayed, she still sees "a high likelihood" that the deal closes, but potentially 4-6 months behind schedule. Young, who sees many players in Inflammation & Immunology that could leverage oral Otezla with their existing salesforce, added that Bristol may not lose much in value from this divestiture if the process is competitive. She keeps a Neutral rating and $100 price target on Celgene shares.
07/17/19
MZHO
07/17/19
NO CHANGE
Target $103
MZHO
Buy
Amgen seen by Mizuho as 'most likely' buyer of Celgene's Otezla
In the wake of the recent announcement that Bristol-Myers (BMY) plans to divest Otezla as part of its deal to acquire Celgene (CELG), Mizuho analyst Salim Syed said he has received questions on who could be a realistic buyer. He believes the "most likely" buyer would be Amgen (AMGN), followed by Johnson & Johnson (JNJ), which he would label as a "likely" buyer. Syed identifies the "less likely, but possible" buyers as Eli Lilly (LLY) and Regeneron (REGN). The analyst, who said Otezla is worth anywhere from $5B-$10B depending on the view of sales and synergy potential, keeps a Buy rating and $103 price target on Celgene shares.
05/28/19
GSCO
05/28/19
INITIATION
Target $54
GSCO
Buy
Bristol-Myers initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Bristol-Myers Squibb with a Buy rating and $54 price target. Bristol-Myers is trading at a "significant discount to the group," Flynn tells investors in a research note. The analyst says his call is based on valuation, and he sees potential for multiple expansion whether or not the Celgene (CELG) acquisition closes.
UMRX Unum Therapeutics
$2.62

-0.01 (-0.38%)

07/03/19
HCWC
07/03/19
NO CHANGE
Target $18
HCWC
Buy
Unum Therapeutics shares overreacted to clinical hold, says H.C. Wainwright
Unum Therapeutics shares overreacted yesterday to news of a clinical hold on the Phase 1 trial ATTCK-20-2, which may provide an attractive entry point, H.C. Wainwright analyst Andrew Fein tells investors in a research note. The analyst says that although the clinical hold raises concerns on potential "narrower-than-expected therapeutic window" of ACTR-087 in B-cell malignancies, his comfort in a positive outlook of ATTCK-20-02 and ACTR-T cells in general is derived from the fact that approved CAR-T therapies, Kymriah and Yescarta, are both associated with similar serious adverse events. The analyst reiterates a Buy rain on Unum Therapeutics with an $18 price target ahead of the company's multiple data in 2019.
07/03/19
COWN
07/03/19
NO CHANGE
COWN
Market Perform
Unum Therapeutics clinical hold not an issue, says Cowen
Cowen analyst Yaron Werber noted the FDA placed a clinical hold on ACTR087 adding to ongoing concerns about the potential of its platform given lackluster efficacy data. The analyst said the hold is not an issue as it was deprioritized and the prospects for the stock may lie in the BOXR platform. Werber maintained his Market Perform rating on Unum Therapeutics shares.
07/03/19
RHCO
07/03/19
NO CHANGE
Target $6
RHCO
Buy
Unum Therapeutics price target lowered to $6 from $10 at SunTrust
SunTrust analyst Peter Lawson lowered his price target on Unum Therapeutics to $6 after yesterday's FDA announcement of a clinical hold on its Phase 1 trial ATTCK-20-2 evaluating ACTR087 in combination with rituximab. The analyst is retaining a Buy rating on the stock however, stating that his discussions with the management indicated the program was already de-prioritized in November of 2018 "in favor of the '707 construct", and the hold should yield a limited read through to other programs.
07/03/19
MSCO
07/03/19
NO CHANGE
Target $18
MSCO
Overweight
Clinical hold not a 'major event' for Unum Therapeutics, says Morgan Stanley
After Unum Therapeutics announced that the FDA has placed a clinical hold on the Phase 1 trial ATTCK-20-2 evaluating Unum's ACTR087 in combination with rituximab, Morgan Stanley analyst Matthew Harrison said he does not view this as a "major event" given that management had previously de-prioritized the program during its earnings call last November. Lead program ACTR707 has reported no DLTs or serious adverse events of CRS or neurotoxicity through the first three patient cohorts as of May 7, noted Harrison, who would argue that ACTR707 "clearly has a different safety profile" than ACTR087. He maintains an Overweight rating on Unum Therapeutics shares.
CLDX Celldex
$2.37

0.01 (0.42%)

ZIOP Ziopharm
$5.49

-0.16 (-2.83%)

11/15/18
RAJA
11/15/18
UPGRADE
RAJA
Outperform
Ziopharm upgraded to Outperform from Market Perform at Raymond James
11/15/18
11/15/18
UPGRADE
Target $5

Outperform
Ziopharm upgraded to Outperform at Raymond James
As previously reported, Raymond James analyst Reni Benjamin upgraded Ziopharm to Outperform from Market Perform, with a $5 price target. The analyst notes that the company provided an update on its cell and gene therapy programs in a recent conference call, saying it has severed its relationship with Intrexon, eliminating $157M million in preferred stock and significantly simplifying its corporate structure. Additionally, Ziopharm said that in conjunction with Steven Rosenberg and the NCI, it plans to utilize the Sleeping Beauty neoantigen platform to generate patient specific TCRs, with the filing of an IND expected by year end 2018/early 2019, he pointed out, adding that a cash infusion of $50M from long-term investors should extend the company's cash runway to Q2 of 2020.
04/01/19
LDLW
04/01/19
INITIATION
Target $7.5
LDLW
Buy
Ziopharm initiated with a Buy at Laidlaw
Laidlaw analyst Yale Jen initiated ZipPharm with a Buy and $7.50 price target.
04/04/19
LSCM
04/04/19
INITIATION
Target $7
LSCM
Buy
Ziopharm initiated with a Buy at Lake Street
Lake Street analyst Thomas Flaten started Ziopharm with a Buy rating and $7 price target. "By unlocking the potential of its Sleeping Beauty technology," Ziopharm is poised to "deliver a leap forward" in the personalization of cancer therapy, Flaten tells investors in a research note. The analyst sees an opportunity for "significant value generation" with near-term clinical catalysts.

TODAY'S FREE FLY STORIES

DDAIF

Daimler AG

$0.00

(0.00%)

15:29
09/18/19
09/18
15:29
09/18/19
15:29
Hot Stocks
China's CATL to supply batteries for Daimler electric trucks »

Daimler Trucks &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DVN

Devon Energy

$26.30

-0.4 (-1.50%)

15:29
09/18/19
09/18
15:29
09/18/19
15:29
Options
Bullish calendar call spread with a delta hedge in Devon Energy Corp »

Bullish calendar call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DVN

Devon Energy

$26.32

-0.38 (-1.42%)

15:28
09/18/19
09/18
15:28
09/18/19
15:28
Options
- Bullish calendar call spread with a delta hedge in Devon Energy Corp »

- Bullish calendar call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBER

Uber

$34.01

-0.27 (-0.79%)

15:27
09/18/19
09/18
15:27
09/18/19
15:27
Recommendations
Uber analyst commentary  »

Uber London operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXC

DXC Technology

$31.86

-0.51 (-1.58%)

15:25
09/18/19
09/18
15:25
09/18/19
15:25
Options
DXC Technology call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYRX

Cryoport

$17.69

-0.06 (-0.34%)

15:20
09/18/19
09/18
15:20
09/18/19
15:20
Hot Stocks
Shelton sees Cryoport becoming 'much broader' supply chain company »

Cryoport (CYRX) provides…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTB

M&T Bank

$158.78

0.66 (0.42%)

15:19
09/18/19
09/18
15:19
09/18/19
15:19
Hot Stocks
M&T Bank lowers prime lending rate to 5.0% from 5.25% »

Effective Thursday,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
09/18/19
09/18
15:17
09/18/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
09/18/19
09/18
15:16
09/18/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
09/18/19
09/18
15:15
09/18/19
15:15
General news
On the policy path: »

On the policy path: the…

SPY

SPDR S&P 500 ETF Trust

$299.06

-1.88 (-0.62%)

, SPX

S&P 500

$0.00

(0.00%)

15:11
09/18/19
09/18
15:11
09/18/19
15:11
General news
Fed Chair says not forecasting a recession »

Federal Reserve Chair…

SPY

SPDR S&P 500 ETF Trust

$299.06

-1.88 (-0.62%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$299.01

-1.93 (-0.64%)

, SPX

S&P 500

$0.00

(0.00%)

15:07
09/18/19
09/18
15:07
09/18/19
15:07
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Powell doesn't think…

SPY

SPDR S&P 500 ETF Trust

$299.01

-1.93 (-0.64%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTCH

Match Group

$77.00

-2.7 (-3.39%)

, IAC

IAC

$230.15

-6.58 (-2.78%)

15:02
09/18/19
09/18
15:02
09/18/19
15:02
Hot Stocks
Match Group names Thomas Gaissmaier as Chief Human Resources Officer »

Match Group (MTCH)…

MTCH

Match Group

$77.00

-2.7 (-3.39%)

IAC

IAC

$230.15

-6.58 (-2.78%)

FOX

Fox Corp.

$32.24

-0.57 (-1.74%)

DIS

Disney

$135.88

-0.36 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 10

    Oct

  • 24

    Oct

SPY

SPDR S&P 500 ETF Trust

$298.51

-2.43 (-0.81%)

, SPX

S&P 500

$0.00

(0.00%)

15:01
09/18/19
09/18
15:01
09/18/19
15:01
General news
Powell says trade policy among things weighing on outlook »

Fed Chair Powell said the…

SPY

SPDR S&P 500 ETF Trust

$298.51

-2.43 (-0.81%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRD

Friedman Industries

$6.12

-0.04 (-0.65%)

15:01
09/18/19
09/18
15:01
09/18/19
15:01
Hot Stocks
Friedman Industries names Michael J. Taylor president, CEO »

Friedman Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
09/18/19
09/18
15:00
09/18/19
15:00
General news
More from Powell: this is a time of difficult judgments and disparate perspectives »

More from Powell: this is…

14:50
09/18/19
09/18
14:50
09/18/19
14:50
General news
Powell in Q&A: on whether this rate cut is still a "mid-cycle adjustment? »

Powell in Q&A: on…

MLHR

Herman Miller

$44.20

-0.3 (-0.67%)

14:49
09/18/19
09/18
14:49
09/18/19
14:49
Options
Herman Miller options imply 12.7% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 21

    Oct

  • 22

    Oct

CYRX

Cryoport

$17.52

-0.23 (-1.30%)

14:47
09/18/19
09/18
14:47
09/18/19
14:47
Hot Stocks
Shelton sees 'bright future' ahead for Cryoport »

Cryoport (CYRX) provides…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$298.64

-2.3 (-0.76%)

, SPX

S&P 500

$0.00

(0.00%)

14:45
09/18/19
09/18
14:45
09/18/19
14:45
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Powell says FOMC has…

SPY

SPDR S&P 500 ETF Trust

$298.64

-2.3 (-0.76%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:45
09/18/19
09/18
14:45
09/18/19
14:45
General news
Chair Powell at the podium: Powell said the Fed cut rates again »

Chair Powell at the…

FITB

Fifth Third

$28.24

0.05 (0.18%)

14:42
09/18/19
09/18
14:42
09/18/19
14:42
Hot Stocks
Fifth Third decreases prime lending rate to 5% »

Fifth Third Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

SPY

SPDR S&P 500 ETF Trust

$298.73

-2.21 (-0.73%)

, SPX

S&P 500

$0.00

(0.00%)

14:41
09/18/19
09/18
14:41
09/18/19
14:41
General news
Fed Chair Powell says more rate cuts could be needed if economy weakens »

Asked if it remains his…

SPY

SPDR S&P 500 ETF Trust

$298.73

-2.21 (-0.73%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:40
09/18/19
09/18
14:40
09/18/19
14:40
General news
FOMC Forecast revisions »

FOMC Forecast revisions,…

SPY

SPDR S&P 500 ETF Trust

$298.88

-2.06 (-0.68%)

, SPX

S&P 500

$0.00

(0.00%)

14:38
09/18/19
09/18
14:38
09/18/19
14:38
General news
Fed Chair says additional signs seen of weakness abroad »

Federal Reserve Chair…

SPY

SPDR S&P 500 ETF Trust

$298.88

-2.06 (-0.68%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.